Cancer BiologybioRxiv
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A. G. Waks, O. Cohen, B. Kochupurakkal…·N. Wagle
This study identifies genomic reversion and increased DNA end resection as mechanisms of resistance to PARP inhibitors and platinum in BRCA1/2-mutant metastatic breast cancer, with RAD51 foci as a potential biomarker.
DOI 10.1016/j.annonc.2020.02.008